Outperform Cancer spotlights sulforaphane research as cancer burden climbs

Outperform Cancer has released a new episode with sulforaphane researcher Dr. Jed W. Fahey as global and U.S. cancer cases continue to rise. The discussion centers on a new peer-reviewed review of sulforaphane’s potential synergies with cancer drugs and why emerging nutrition science may matter for patients and clinicians. Why it matters: - Global cancer burden is at record levels, with more than 18.5 million new diagnoses in 2023 and projections of 30.5 million annual cases by 2050. - More than 40% of cancer deaths worldwide are linked to modifiable risk factors, including diet. - Outperform Cancer is trying to move emerging research out of academic journals and into public conversation for patients, caregivers and health professionals. What happened: - Outperform Cancer featured Dr. Jed W. Fahey in a new episode titled “Can Broccoli Sprouts Fight Cancer? What 30 Years of Research Shows.” - The episode focuses on sulforaphane, a phytochemical first isolated as a cancer-preventive compound in 1992 by the late Dr. Paul Talalay at Johns Hopkins University School of Medicine. - The platform was founded by metastatic cancer survivor Marybeth Gilliam. The details: - Sulforaphane has been the subject of more than 3,000 published studies and now has 136 published human clinical studies. - A peer-reviewed paper in Medicines in May 2026 reviewed evidence on potential synergies between sulforaphane and cancer treatment drugs. - The review covered eleven cancer types: bladder, blood, brain, breast, colon, esophageal, liver, lung, ovarian, prostate and skin cancers. - The paper found preclinical and emerging translational evidence suggesting sulforaphane may affect treatment response, tolerability and therapeutic effectiveness when combined with certain conventional therapies. - In the episode, Fahey discusses sulforaphane’s mechanisms of action, including activation of the body’s cellular defense and detoxification pathways and possible effects on cancer stem cells. - Outperform Cancer describes itself as a science-driven media and education platform focused on prevention, survivorship, nutrition and healthspan. Between the lines: - The project reflects a broader push to make early-stage nutrition and cancer research more accessible before it reaches standard clinical practice. - The timing is notable because rising cancer incidence is increasing interest in complementary lines of research alongside conventional treatment. - The sulforaphane work remains an emerging area of study, so the strongest claims in the release are based on preclinical and translational evidence rather than definitive clinical proof. What’s next: - Outperform Cancer is directing listeners to the episode and related publication for more context on the sulforaphane research. - Fahey’s publication, “Sulforaphane Synergies with Phytochemicals and Pharmaceuticals: Implications for Healthspan,” is available through the journal DOI . - The company’s site is outperformcancer.com , with additional channels on Instagram, YouTube and Spotify. The bottom line: - As cancer rates climb, Outperform Cancer is positioning sulforaphane as a promising but still emerging area where nutrition science and oncology may intersect.